Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial
AffiliationAddis Ababa University, Ethiopia; Institute of Endemic Diseases, University of Khartoum, Sudan; Centre for Clinical Research, Kenya Medical Research Institute, Kenya; Medecins Sans Frontieres, Amsterdam; Drugs for Neglected Diseases initiative (DNDi), Switzerland; Gondar University, Ethiopia; Arba Minch Hospital, Regional Health Bureau of SNNP state, Ethiopia; Faculty of Medicine, Gedaref University, Sudan; London School of Hygiene and Tropical Medicine, United Kingdom
MetadataShow full item record
JournalPLoS Neglected Tropical Diseases
AbstractVisceral leishmaniasis (VL) is a major health problem in developing countries. The untreated disease is fatal, available treatment is expensive and often toxic, and drug resistance is increasing. Improved treatment options are needed. Paromomycin was shown to be an efficacious first-line treatment with low toxicity in India.